Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

InMed Pharmaceuticals (INM) EPS (Weighted Average and Diluted): 2023-2025

Historic EPS (Weighted Average and Diluted) for InMed Pharmaceuticals (INM) over the last 3 years, with Jun 2025 value amounting to -$8.36.

  • InMed Pharmaceuticals' EPS (Weighted Average and Diluted) rose 83.76% to -$0.44 in Q3 2025 from the same period last year, while for Sep 2025 it was -$6.45, marking a year-over-year increase of 52.78%. This contributed to the annual value of -$8.36 for FY2025, which is 58.49% up from last year.
  • As of FY2025, InMed Pharmaceuticals' EPS (Weighted Average and Diluted) stood at -$8.36, which was up 58.49% from -$20.14 recorded in FY2024.
  • InMed Pharmaceuticals' EPS (Weighted Average and Diluted)'s 5-year high stood at -$3.25 during FY2023, with a 5-year trough of -$20.14 in FY2024.
  • Its 3-year average for EPS (Weighted Average and Diluted) is -$10.58, with a median of -$8.36 in 2025.
  • Its EPS (Weighted Average and Diluted) has fluctuated over the past 5 years, first crashed by 520.46% in 2024, then soared by 58.49% in 2025.
  • InMed Pharmaceuticals' EPS (Weighted Average and Diluted) (Yearly) stood at -$3.25 in 2023, then crashed by 520.46% to -$20.14 in 2024, then skyrocketed by 58.49% to -$8.36 in 2025.